AbESTT

AbESTT

A trial that assessed abciximab as an alternative to tPA in strokes
Conclusions Patients receiving abciximab were 20% more likely to have a better outcome; neurologic recovery was 29% in the treated group vs. 16% in placebo patients
References in periodicals archive ?
The Abciximab in Emergent Stroke Treatment Trial (AbESTT II) uses abciximab within 5 hours of stroke symptom onset and the Combined Approach to Lysis Utilizing Epiifibatide in Acute Ischemic Stroke (CLEAR) trial uses eptifibatide in combination with tPA within 3 hours of acute ischemic stroke.
Abciximab was used as a solo agent in 394 patients in 0-6 hours after an ischemic stroke, in a randomized, double-blind, placebo-controlled study conducted at 38 sites in North America and Europe and known as the Abciximab in Emergent Stroke Treatment Trial (AbESTT).